Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Guangxi
-
Hezhou, Guangxi, China, 542899
- Recruiting
- Hezhou Center for Disease Control and Prevention
-
Contact:
- Jianbiao Li
- Phone Number: 86-13635076356
- Email: 309551925@qq.com
-
Luzhai, Guangxi, China, 545699
- Not yet recruiting
- Luzhai Center for Disease Control and Prevention
-
Contact:
- Baowei Guang
- Phone Number: 86-0772-6812646
- Email: lzjkxmb@126.com
-
Sanjiang, Guangxi, China, 545500
- Not yet recruiting
- Sanjiang Center for Disease Control and Prevention
-
Contact:
- Xue Yang
- Phone Number: 86-13100499521
- Email: sjjkxmk@163.com
-
Zhongshan, Guangxi, China, 542600
- Recruiting
- Zhongshan Center for Disease Control and Prevention
-
Contact:
- Guide Nong
- Phone Number: 86-13321645288
- Email: ngd006@163.com
-
-
Hebei
-
Handan, Hebei, China, 056011
- Not yet recruiting
- Yongnian Center for Disease Control and Prevention
-
Contact:
- Zhimin Liu
- Phone Number: 86-19932006666
- Email: liuzhimin199@163.com
-
Yuanshi, Hebei, China, 051130
- Not yet recruiting
- Yuanshi Center for Disease Control and Prevention
-
Contact:
- Licheng Qi
- Phone Number: 86-13582332166
- Email: qilicheng@126.com
-
-
Sichuan
-
Panzhihua, Sichuan, China, 617000
- Not yet recruiting
- Panzhihua Center for Disease Control and Prevention
-
Contact:
- Meixian Liu
- Phone Number: 86-18090406818
- Email: 449048010@qq.com
-
Zigong, Sichuan, China, 643000
- Not yet recruiting
- Zigong Center for Disease Control and Prevention
-
Contact:
- Qun Li
- Phone Number: 86-18990086037
- Email: lqzgcdc@163.com
-
Zigong, Sichuan, China, 643299
- Not yet recruiting
- Fushun Center for Disease Control and Prevention
-
Contact:
- Yongbin Hu
- Phone Number: 86-18990018665
- Email: 418299275@qq.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Infants and children aged from 3 months to 5 years old;
- The legal representative voluntarily agrees to participate in the study and signed the informed consent form;
- The legal representative voluntarily agrees to comply with the requirements of the clinical study protocol, and they can participate in all planned follow-up;
- Subjects who didn't immuned with attenuated live vaccine within 14 days and inactivated vaccine within 7 days before vaccination;
- Axillary temperature ≤37.0℃;
- According to the medical history, physical examination and the judgment of the researcher, it is determined that the subject is in good physical condition.
Exclusion Criteria:
- Previous proven history of bacillary dysentery;
- Subjects who are allergic to tetanus toxoid, and have any history of other vaccination or drug allergy, or a fever above 39.5 ℃ after previous vaccination;
- Within 3 days before vaccination, suffering from acute diseases or in the acute episode of chronic disease or using antipyretic, analgesic and antiallergic drugs (such as acetaminophen, ibuprofen, etc.);
- Had severe bowel disease, and had symptoms such as diarrhea, abdominal pain, pus and blood stool and other symptoms in the past 3 days;
- With pathological jaundice confirmed by existing diagnosis;
- History of thrombocytopenia or other coagulation disorders with definite diagnosis;
- Known or suspected immunological deficiency (such as perianal abscess, which indicates that infants may have immune deficiency), and received long-term (≥14 days) immunosuppressive therapy (radiotherapy, chemotherapy, systemic glucocorticosteroids≥2 mg/kg/day, antimetabolic drugs and cytotoxic drugs) within half a year before vaccination, or confirmed that the parents were HIV infected;
- Received immunoglobulin / blood products treatment within 3 months before vaccination;
- Severe congenital malformations (functional impairment of important organs), severe malnutrition, developmental disorders and serious genetic diseases (such as severe thalassemia);
Subjects with the following diseases:
- Serious liver and kidney diseases, cardiovascular diseases, malignant tumors and other chronic diseases;
- Diagnosis with infectious diseases such as tuberculosis, viral hepatitis and so on;
- Severe asthma;
- Systemic rash, dermatophyte, skin suppuration or blister;
- History or family history of convulsion, epilepsy, encephalopathy, mental illness;
- Planning to participate or currently participating in clinical trials of other vaccines or drugs;
- Any situation that the investigator believed may affect the study evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental group
S. Flexneriza-S.
Sonnei Bivalent Conjugate Vaccine, 0.5ml/dose, 2 doses with an interval of 30 days.
|
Single intramuscular dose contains 10 µg of S. flexneri 2a polysaccharide and S. sonnei polysaccharide respectively.
|
|
Placebo Comparator: Placebo group
Aluminium phosphate adjuvant, 0.5ml/dose, 2 doses with an interval of 30 days.
|
Single intramuscular dose contains 0.15~0.25 mg of aluminum ion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy study of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine as assessed by protective rate
Time Frame: 30 day after each vaccination
|
Evaluate the protective rate for bacillary dysentery
|
30 day after each vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Lin Du, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021080C
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.